Biggest News Aggregation in the World
๐Ÿ“ฐ Advanced Solid Tumors News

Advanced Solid Tumors News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting

NKGen Biotech, Inc. announced an online publication, titled ?Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity...
United States Mccormick Place Nkgen Biotech Inc Mccormick Place Convention Center American Society Of Clinical Oncology Interim Analysis

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation

EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April...
United States Kaitlyn Nealy Julia Neugebauer Thomas Biegi American Society Of Clinical Oncology Lymphoma Society

The emotional trial of clinical trials, part 1: It's like online dating except if you choose wrong you die « The Story's Story

Part 1 is mostly about what happened as Bess and I raced against tumor growth to find a new clinical trial that might keep me alive. Part 2 will be published Thursday, and it is mostly about how this process feels and what could be done differentlyโ€”and better. If you find this essay useful or…
New York United States San Diego San Antonio Salt Lake City Tisotumab Vedotin

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPARโบ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data,...
United States Sylvia Wheeler Aljanae Reynolds Sam Whiting Cancer Research Communications Exchange Commission On

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science